Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches

Atherosclerotic cardiovascular disease (ASCVD) represents a long‐standing health care burden in most industrialized countries. Management of ASCVD is multifaceted, and utilization of antithrombotic agents is a key component of care to reduce vascular events. Minimizing thrombotic risk can be accompl...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2017-12, Vol.37 (12), p.1545-1564
Main Authors: Jenkins, Antoine T., Kantorovich, Alexander, Burman, Luba
Format: Article
Language:English
Subjects:
Anticoagulants
Anticoagulants - adverse effects
Anticoagulants - therapeutic use
anticoagulation
antiplatelet
Antiplatelet therapy
Arteriosclerosis
aspirin
atherosclerosis
bleeding
Cardiovascular diseases
Complications
direct oral anticoagulants (DOACs)
Drug Therapy, Combination - adverse effects
Fibrinolytic Agents - adverse effects
Fibrinolytic Agents - therapeutic use
Guidelines as Topic
Hemorrhage - chemically induced
Humans
P2Y12 inhibitor
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
thrombosis
Thrombosis - drug therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atherosclerotic cardiovascular disease (ASCVD) represents a long‐standing health care burden in most industrialized countries. Management of ASCVD is multifaceted, and utilization of antithrombotic agents is a key component of care to reduce vascular events. Minimizing thrombotic risk can be accomplished via antiplatelet or anticoagulant drugs; however, combination therapy is warranted for some indications. Although reducing thrombotic complications is important, it is equally vital to consider the safety of combination regimens. Thus clinicians must effectively balance both individualized thrombotic and bleeding risks when using this strategy. Scenarios occur in practice when determining the role for combination therapy is not clear, especially for patients with ASCVD who require both dual antiplatelet therapy plus anticoagulation. The aim of this review is to discuss the role of dual or triple antithrombotic therapies across the spectrum of thrombotic disease states. In addition to critiquing relevant research studies and evaluating key recommendations from nationally published guidelines and consensus statements involving the use of these agents, we offer practical considerations that can be utilized when managing patients with ASCVD.
ISSN:0277-0008
1875-9114
DOI:10.1002/phar.2041